Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$1,051.03 0.17 (0.02%) as of 4:30 Fri 6/28


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 110.03(B)
Last Volume: 750,617 Avg Vol: 759,306
52 Week Range: $692.45 - $1071.19
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 192,108 255,165 311,759 469,743
Total Sell Value $188,697,290 $247,812,013 $294,950,701 $405,465,351
Total People Sold 7 14 16 18
Total Sell Transactions 18 43 67 128
End Date 2024-03-31 2023-12-29 2023-06-30 2022-06-30

   
Records found: 2430
  Page 45 of 98  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Brown Michael S Director   –       •      –    2017-03-29 4 AS $400.00 $400,000 D/D (1,000) 0     -
   Brown Michael S Director   –       •      –    2017-03-29 4 OE $177.82 $177,820 D/D 1,000 1,000     -
   Sanofi-Aventis   •       •       •   2017-01-11 4 B $362.47 $32,274,872 I/I 87,298 23,505,694 2.64     -
   Vagelos P Roy Chairman of the Board   •       •      –    2017-01-03 4 GD $0.00 $0 I/I 571 151,254     -
   Sing George L Director   –       •      –    2017-01-03 4 OE $19.69 $137,830 D/D 7,000 119,772     -
   Yancopoulos George President & CSO   •       •      –    2016-12-20 5 GD $0.00 $0 I/I 3,918 64,058     -
   Yancopoulos George President and CSO   •       •      –    2016-12-16 4 GA $0.00 $0 I/I 89,427 159,324     -
   Yancopoulos George President and CSO   •       •      –    2016-12-16 4 GD $0.00 $0 D/D 89,427 500,000     -
   Schleifer Leonard S President & CEO   •       •      –    2016-12-15 4 D $380.09 $51,463,046 D/D (135,397) 157,409     -
   Schleifer Leonard S President & CEO   •       •      –    2016-12-15 4 OE $20.32 $5,080,000 D/D 250,000 292,806     -
   Yancopoulos George President Regeneron Laboratori   •       •      –    2016-12-15 4 D $380.09 $40,157,269 D/D (105,652) 591,348     -
   Yancopoulos George President Regeneron Laboratori   •       •      –    2016-12-15 4 OE $20.32 $3,964,005 D/D 195,079 697,000     -
   Baker Charles A Director   –       •      –    2016-12-12 4 AS $390.67 $1,176,048 D/D (3,000) 9,000     -
   Baker Charles A Director   –       •      –    2016-12-12 4 OE $18.61 $55,830 D/D 3,000 12,000     -
   Vagelos P Roy Chairman of the Board   •       •      –    2016-11-22 4 GD $0.00 $0 D/D 59,788 414,156     -
   Ryan Arthur F Director   –       •      –    2016-11-15 4 GD $0.00 $0 D/D 1,000 35,500     -
   Ryan Arthur F Director   –       •      –    2016-11-15 4 S $429.34 $858,680 D/D (2,000) 36,500     -
   Goldstein Joseph L Director   –       •      –    2016-11-14 4 AS $450.00 $956,250 D/D (2,125) 13,000     -
   Goldstein Joseph L Director   –       •      –    2016-11-14 4 OE $273.67 $581,549 D/D 2,125 15,125     -
   Stahl Neil EVP Research and Development   •       –      –    2016-11-07 4 GD $0.00 $0 D/D 7,876 23,950     -
   Vagelos P Roy Chairman of the Board   •       •      –    2016-11-07 4 D $355.52 $14,854,337 D/D (41,782) 473,944     -
   Vagelos P Roy Chairman of the Board   •       •      –    2016-11-07 4 OE $20.32 $1,562,506 D/D 76,895 515,726     -
   Vagelos P Roy Chairman of the Board   •       •      –    2016-10-03 4 GD $0.00 $0 I/I 531 151,825     -
   Larosa Joseph J SVP General Counsel and Secret   •       –      –    2016-09-01 4 D $392.63 $1,940,770 D/D (4,943) 11,813     -
   Goldstein Joseph L Director   –       •      –    2016-07-29 4 AS $425.00 $903,125 D/D (2,125) 13,000     -
  2430 Records found
  Previous  40  41  42  43  44  45  46  47  48  49  Next   
  Page 45 of 98
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us